We have seen a great increase in use of Ofirmev. I believe the SGA costs are still large. Time for a big boy to step in and cut SGA costs. BAXTER comes to mind since DESFLURANE is losing patent protection. I am predicting a 1 billion buyout by BAX. Heck, they even make the stuff in their own factory. Convenient.